Cardiovascular

Latest News

FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension

March 25th 2024

J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.

FDA Approves Drug that Treats Hypertension in a New Way
FDA Approves Drug that Treats Hypertension in a New Way

March 21st 2024

ckybe-stock.adobe.com
FDA Sets PDUFA Date for Acoramidis in Heart Failure Indication

February 5th 2024

Express Scripts Lists Inpefa as Preferred on Medicare Formularies
Express Scripts Lists Inpefa as Preferred on Medicare Formularies

October 10th 2023

FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication
FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication

October 9th 2023

More News

© 2024 MJH Life Sciences

All rights reserved.